News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.

Articles by safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.

Double-Blinded Extension of the RADIANCE Trial Demonstrates the Efficacy and Safety of Ozanimod in Patients With Multiple Sclerosis

ByCohen JA, Comi G, Arnold DL, et al,RADIANCE Trial Investigators. Efficacy,safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.

January 18th 2019

Latest Updated Articles

Double-Blinded Extension of the RADIANCE Trial Demonstrates the Efficacy and Safety of Ozanimod in Patients With Multiple Sclerosis
January 18th 2019

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access